PCSK9 and coronary artery disorder: There is strong evidence that ceramide scores (CERT1 and CERT2) can be used to select CHD patients who have the highest risk and may benefit from more thorough examinations and perhaps more aggressive treatments such as PCSK9 inhibitor or methotrexate.